J.W. Cole Advisors Inc. Acquires 259 Shares of Bristol-Myers Squibb (NYSE:BMY)

J.W. Cole Advisors Inc. lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 20,121 shares of the biopharmaceutical company’s stock after purchasing an additional 259 shares during the period. J.W. Cole Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $1,138,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in BMY. AMF Tjanstepension AB grew its holdings in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after acquiring an additional 39,419 shares during the last quarter. Swedbank AB grew its holdings in Bristol-Myers Squibb by 0.9% in the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock worth $162,440,000 after acquiring an additional 28,427 shares during the last quarter. Cyndeo Wealth Partners LLC grew its holdings in Bristol-Myers Squibb by 3.9% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 9,535 shares of the biopharmaceutical company’s stock worth $493,000 after acquiring an additional 357 shares during the last quarter. Vest Financial LLC bought a new stake in Bristol-Myers Squibb in the 3rd quarter worth $438,000. Finally, Raleigh Capital Management Inc. grew its holdings in Bristol-Myers Squibb by 42.7% in the 3rd quarter. Raleigh Capital Management Inc. now owns 42,480 shares of the biopharmaceutical company’s stock worth $2,198,000 after acquiring an additional 12,705 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Daiwa America raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Morgan Stanley raised their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Up 1.0 %

Shares of Bristol-Myers Squibb stock opened at $54.45 on Wednesday. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The stock has a market capitalization of $110.49 billion, a PE ratio of -12.32, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10. The company has a 50-day simple moving average of $57.11 and a two-hundred day simple moving average of $54.19.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. On average, analysts anticipate that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.56%. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.